These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

426 related articles for article (PubMed ID: 34828946)

  • 1. Bioactivity of Dietary Polyphenols: The Role in LDL-C Lowering.
    Sun P; Zhao L; Zhang N; Zhou J; Zhang L; Wu W; Ji B; Zhou F
    Foods; 2021 Nov; 10(11):. PubMed ID: 34828946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low-density lipoprotein apheresis: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2007; 7(5):1-101. PubMed ID: 23074505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Perspectives on low-density lipoprotein cholesterol goal achievement.
    Catapano AL
    Curr Med Res Opin; 2009 Feb; 25(2):431-47. PubMed ID: 19192988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polyphenols and atherosclerosis: A critical review of clinical effects on LDL oxidation.
    Ahmadi A; Jamialahmadi T; Sahebkar A
    Pharmacol Res; 2022 Oct; 184():106414. PubMed ID: 36028188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Further Lowering of Low-Density Lipoprotein Cholesterol in Patients Starting With Very Low Levels: A Meta-analysis.
    Sabatine MS; Wiviott SD; Im K; Murphy SA; Giugliano RP
    JAMA Cardiol; 2018 Sep; 3(9):823-828. PubMed ID: 30073316
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lowering Targeted Atherogenic Lipoprotein Cholesterol Goals for Patients at "Extreme" ASCVD Risk.
    Rosenblit PD
    Curr Diab Rep; 2019 Nov; 19(12):146. PubMed ID: 31754844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Models for describing relations among the various statin drugs, low-density lipoprotein cholesterol lowering, pleiotropic effects, and cardiovascular risk.
    Robinson JG
    Am J Cardiol; 2008 Apr; 101(7):1009-15. PubMed ID: 18359323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aronia berry polyphenol consumption reduces plasma total and low-density lipoprotein cholesterol in former smokers without lowering biomarkers of inflammation and oxidative stress: a randomized controlled trial.
    Xie L; Vance T; Kim B; Lee SG; Caceres C; Wang Y; Hubert PA; Lee JY; Chun OK; Bolling BW
    Nutr Res; 2017 Jan; 37():67-77. PubMed ID: 28215316
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of Hypercholesterolemia, Appropriateness of Therapeutic Approaches and New Drugs in Patients with High Cardiovascular Risk.
    Agabiti Rosei E; Salvetti M
    High Blood Press Cardiovasc Prev; 2016 Sep; 23(3):217-30. PubMed ID: 27567901
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evolving Management of Low-Density Lipoprotein Cholesterol: A Personalized Approach to Preventing Atherosclerotic Cardiovascular Disease Across the Risk Continuum.
    Wilkinson MJ; Lepor NE; Michos ED
    J Am Heart Assoc; 2023 Jun; 12(11):e028892. PubMed ID: 37260036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New Strategies for Lowering Low Density Lipoprotein Cholesterol for Cardiovascular Disease Prevention.
    Gaine SP; Quispe R; Patel J; Michos ED
    Curr Cardiovasc Risk Rep; 2022 Sep; 16(9):69-78. PubMed ID: 36213094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above: Analyses From the WOSCOPS (West of Scotland Coronary Prevention Study) 5-Year Randomized Trial and 20-Year Observational Follow-Up.
    Vallejo-Vaz AJ; Robertson M; Catapano AL; Watts GF; Kastelein JJ; Packard CJ; Ford I; Ray KK
    Circulation; 2017 Nov; 136(20):1878-1891. PubMed ID: 28877913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Residual Atherosclerotic Cardiovascular Disease Risk: Focus on Non-High-Density Lipoprotein Cholesterol.
    Luo Y; Peng D
    J Cardiovasc Pharmacol Ther; 2023; 28():10742484231189597. PubMed ID: 37641208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-density lipoprotein cholesterol: how low can we go?
    Sherbet DP; Garg P; Brilakis ES; Banerjee S
    Am J Cardiovasc Drugs; 2013 Aug; 13(4):225-32. PubMed ID: 23609530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New Insights in the Control of Low-Density Lipoprotein Cholesterol to Prevent Cardiovascular Disease.
    Katzmann JL; Laufs U
    Curr Cardiol Rep; 2019 Jun; 21(8):69. PubMed ID: 31227914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
    Sahebkar A; Watts GF
    Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging lipid lowering agents targeting LDL cholesterol.
    Wójcik C
    Postgrad Med; 2020 Jun; 132(5):433-440. PubMed ID: 32243228
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 22.